12 years of historical data (2013–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
ImmunityBio, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $9.6B | $1.8B | $2.6B | $2.0B | $2.4B | $5.1B | $1.5B | $377M | $1.4B | $1.9B | $5.7B |
| Enterprise Value | $10.0B | $2.2B | $3.0B | $2.6B | $2.8B | $5.3B | $1.5B | $367M | $1.4B | $1.9B | $5.5B |
| P/E Ratio → | -15.77 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 653.30 | 121.61 | 4105.07 | 8447.89 | 2533.77 | 8442.61 | 33773.25 | 8022.39 | 31544.39 | 42711.99 | 23960.84 |
| P/B Ratio | — | — | — | — | — | — | 12.03 | 2.82 | 6.49 | 6.40 | 15.88 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 146.07 | 4846.66 | 11027.60 | 3031.16 | 8840.35 | 33757.90 | 7811.52 | 31175.41 | 42714.87 | 23225.93 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
ImmunityBio, Inc. earns an operating margin of -2334.2%. Operating margins have expanded from -146374.2% to -2334.2% over the past 3 years, signaling improving operational efficiency.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -20858.1% | 6717.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -2334.2% | -2334.2% | -58239.5% | -146374.2% | -35361.9% | -36509.1% | -155597.7% | -209338.3% | -220266.7% | -282954.5% | -101218.6% |
| Net Profit Margin | -2804.8% | -2804.8% | -93761.4% | -173569.6% | -37129.6% | -36669.6% | -152997.7% | -204736.2% | -214273.3% | -274565.9% | -100371.2% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | -20269.6% | -51.7% | -54.6% | -37.6% | -37.2% | -114.3% |
| ROA | -93.2% | -93.2% | -134.6% | -100.2% | -100.5% | -121.7% | -40.5% | -44.5% | -34.0% | -35.3% | -110.8% |
| ROIC | — | — | -1217.1% | -135.1% | -144.5% | -136.8% | -41.2% | -45.3% | -30.0% | -39.2% | -196.7% |
| ROCE | -88.9% | -88.9% | -235.5% | — | -260.9% | -155.1% | -46.7% | -51.2% | -37.1% | -37.4% | -114.0% |
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $361M ($504M total debt minus $143M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 0.12 | 0.05 | 0.03 | 0.03 | 0.01 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | — | -0.01 | -0.07 | -0.08 | 0.00 | -0.49 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -2.61 | -2.61 | -4.18 | -7.45 | -22.24 | -24.34 | -11.30 | -227.23 | -160.39 | -1886.36 | — |
Short-term solvency ratios and asset-utilisation metrics
ImmunityBio, Inc.'s current ratio of 3.36x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 0.28x to 3.36x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.36 | 3.36 | 5.05 | 0.28 | 0.91 | 1.64 | 4.82 | 3.26 | 6.35 | 16.34 | 48.40 |
| Quick Ratio | 3.21 | 3.21 | 5.05 | 0.28 | 0.91 | 1.64 | 4.82 | 3.26 | 6.35 | 16.34 | 48.40 |
| Cash Ratio | 2.73 | 2.73 | 4.57 | 0.21 | 0.86 | 1.41 | 4.47 | 2.72 | 6.14 | 15.85 | 47.86 |
| Asset Turnover | — | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 65.67 | 1859.04 | 2874.38 | 520.93 | 1208.42 | 2571.98 | 94496.17 | 10203.78 | — | 2743.69 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
ImmunityBio, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.2% | 0.1% | 1.1% | 0.8% | 0.1% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 0.0% | 0.2% | 0.1% | 1.1% | 0.8% | 0.1% |
| Shares Outstanding | — | $700M | $509M | $400M | $389M | $383M | $383M | $325M | $316M | $329M | $326M |
Compare IBRX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| IBRXYou | $10B | -15.8 | — | — | 100.0% | -2334.2% | — | — | — |
| RVMD | $20B | -17.1 | — | — | — | — | -58.1% | -54.3% | — |
| INCY | $20B | 15.8 | 11.9 | 14.8 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
| GMAB | $18B | 15.4 | 14.9 | 15.1 | 95.4% | 31.1% | 23.0% | 22.2% | 0.1 |
| EXEL | $12B | 15.8 | 13.2 | 13.4 | — | 37.6% | 35.5% | 32.1% | 0.2 |
| MRUS | $7B | -26.9 | — | — | 37.2% | -753.0% | -41.4% | -74.6% | — |
| CELC | $5B | -39.5 | — | — | — | — | -87.5% | -50.3% | — |
| CGON | $5B | -41.7 | — | — | 100.0% | -10067.3% | -19.2% | -26.3% | — |
| ERAS | $4B | -19.8 | — | — | — | — | -43.7% | -39.2% | — |
| IDYA | $3B | -25.2 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
| RCUS | $3B | -6.2 | — | — | — | -156.3% | -63.3% | -64.1% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 12 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how IBRX stacks up against sector leader Revolution Medicines, Inc..
Start ComparisonImmunityBio, Inc.'s current P/E ratio is -15.8x. This places it at the 50th percentile of its historical range.
Based on historical data, ImmunityBio, Inc. is trading at a P/E of -15.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
ImmunityBio, Inc. has 100.0% gross margin and -2334.2% operating margin.